The immunomodulatory effect of respective C5aR1 ligands on LPS-induced cytokine release was assessed in primary human macrophages as previously described (34). HMDMs were seeded in 96-well TC plates (100,000/well) for 24 h before treatment. All ligands were prepared in serum-free IMDM containing 0.1% BSA. For stimulation, the cells were co-treated with LPS and respective C5aR1 ligands for 24 h (37 °C, 5% C02). The supernatant was collected and stored at −20 °C till use. IL-6 levels in the supernatant were quantified using respective human ELISA kits (BD OptEIA) as per the manufacturer's protocol.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.